Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Research

MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance

Authors: Richard Ottman, Camha Nguyen, Robert Lorch, Ratna Chakrabarti

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Background

Development of resistance to androgen deprivation therapy (ADT) is a major obstacle for the management of advanced prostate cancer. Therapies with androgen receptor (AR) antagonists and androgen withdrawal initially regress tumors but development of compensatory mechanisms including AR bypass signaling leads to re-growth of tumors. MicroRNAs (miRNAs) are small regulatory RNAs that are involved in maintenance of cell homeostasis but are often altered in tumor cells.

Results

In this study, we determined the association of genome wide miRNA expression (1113 unique miRNAs) with development of resistance to ADT. We used androgen sensitive prostate cancer cells that progressed to ADT and AR antagonist Casodex (CDX) resistance upon androgen withdrawal and treatment with CDX. Validation of expression of a subset of 100 miRNAs led to identification of 43 miRNAs that are significantly altered during progression of cells to treatment resistance. We also show a correlation of altered expression of 10 proteins targeted by some of these miRNAs in these cells.

Conclusions

We conclude that dynamic alterations in miRNA expression occur early on during androgen deprivation therapy, and androgen receptor blockade. The cumulative effect of these altered miRNA expression profiles is the temporal modulation of multiple signaling pathways promoting survival and acquisition of resistance. These early events are driving the transition to castration resistance and cannot be studied in already developed CRPC cell lines or tissues. Furthermore our results can be used a prognostic marker of cancers with a potential to be resistant to ADT.
Appendix
Available only for authorised users
Literature
1.
Javidan J, Deitch AD, Shi XB, de Vere White RW: The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest. 2005, 23: 520-528. 10.1080/07357900500202721PubMed
2.
Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H: Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer. 1999, 81: 242-251. 10.1038/sj.bjc.6690684PubMedCentralPubMed
3.
Seruga B, Ocana A, Tannock IF: Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 2011, 8: 12-23. 10.1038/nrclinonc.2010.136PubMed
4.
Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD: Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004, 11: 459-476. 10.1677/erc.1.00525PubMed
5.
Feldman BJ, Feldman D: The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001, 1: 34-45. 10.1038/35094009PubMed
6.
Gao M, Ossowski L, Ferrari AC: Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. J Cell Physiol. 1999, 179: 336-346. 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-QPubMed
7.
Powell SM, Christiaens V, Voulgaraki D, Waxman J, Claessens F, Bevan CL: Mechanisms of androgen receptor signalling via steroid receptor coactivator-1 in prostate. Endocr Relat Cancer. 2004, 11: 117-130. 10.1677/erc.0.0110117PubMed
8.
Jenster G: Ligand-independent activation of the androgen receptor in prostate cancer by growth factors and cytokines. J Pathol. 2000, 191: 227-228. 10.1002/1096-9896(200007)191:3<227::AID-PATH636>3.0.CO;2-3PubMed
9.
Berrevoets CA, Umar A, Brinkmann AO: Antiandrogens: selective androgen receptor modulators. Mol Cell Endocrinol. 2002, 198: 97-103. 10.1016/S0303-7207(02)00373-8PubMed
10.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL: Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004, 10: 33-39. 10.1038/nm972PubMed
11.
Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C: Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010, 28: 1489-1495. 10.1200/JCO.2009.24.6819PubMedCentralPubMed
12.
Lee YF, Lin WJ, Huang J, Messing EM, Chan FL, Wilding G, Chang C: Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res. 2002, 62: 6039-6044.PubMed
13.
Everley PA, Krijgsveld J, Zetter BR, Gygi SP: Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics. 2004, 3: 729-735. 10.1074/mcp.M400021-MCP200PubMed
14.
Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136: 215-233. 10.1016/j.cell.2009.01.002PubMedCentralPubMed
15.
Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A: Identification of mammalian microRNA host genes and transcription units. Genome Res. 2004, 14: 1902-1910. 10.1101/gr.2722704PubMedCentralPubMed
16.
Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6: 857-866. 10.1038/nrc1997PubMed
17.
Stefani G: Roles of microRNAs and their targets in cancer. Expert Opin Biol Ther. 2007, 7: 1833-1840. 10.1517/14712598.7.12.1833PubMed
18.
Filipowicz W, Bhattacharyya SN, Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?. Nat Rev Genet. 2008, 9: 102-114.PubMed
19.
Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005, 433: 769-773. 10.1038/nature03315PubMed
20.
Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R: miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res. 2009, 69: 7165-7169. 10.1158/0008-5472.CAN-09-1448PubMedCentralPubMed
21.
Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009, 69: 3356-3363. 10.1158/0008-5472.CAN-08-4112PubMedCentralPubMed
22.
Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, Tepper CG, Evans CP, Kung HJ, deVere White RW: An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A. 2007, 104: 19983-19988. 10.1073/pnas.0706641104PubMedCentralPubMed
23.
Jalava SE, Urbanucci A, Latonen L, Waltering KK, Sahu B, Janne OA, Seppala J, Lahdesmaki H, Tammela TL, Visakorpi T: Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 2012, 31: 4460-4471. 10.1038/onc.2011.624PubMed
24.
Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S: Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity. Prostate. 2005, 65: 287-298. 10.1002/pros.20285PubMed
25.
Wang Z, Liu M, Zhu H, Zhang W, He S, Hu C, Quan L, Bai J, Xu N: miR-106a Is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS. Molecular carcinogenesis. 2012, 52: 634-646.PubMed
26.
Satzger I, Mattern A, Kuettler U, Weinspach D, Voelker B, Kapp A, Gutzmer R: MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer. 2010, 126: 2553-2562.PubMed
27.
Chen L, Jiang M, Yuan W, Tang H: miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg: Off J Acad Surg Res. 2012, 25: 156-161. 10.3109/08941939.2011.618523.
28.
Wu CW, Dong YJ, Liang QY, He XQ, Ng SS, Chan FK, Sung JJ, Yu J: MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS ONE. 2013, 8: e57036- 10.1371/journal.pone.0057036PubMedCentralPubMed
29.
Xie H, Zhao Y, Caramuta S, Larsson C, Lui WO: miR-205 expression promotes cell proliferation and migration of human cervical cancer cells. PLoS ONE. 2012, 7: e46990- 10.1371/journal.pone.0046990PubMedCentralPubMed
30.
Kang HW, Wang F, Wei Q, Zhao YF, Liu M, Li X, Tang H: miR-20a promotes migration and invasion by regulating TNKS2 in human cervical cancer cells. FEBS Lett. 2012, 586: 897-904. 10.1016/j.febslet.2012.02.020PubMed
31.
Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ: EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010, 70: 8822-8831. 10.1158/0008-5472.CAN-10-0638PubMed
32.
Shibahara Y, Miki Y, Onodera Y, Hata S, Chan MS, Yiu CC, Loo TY, Nakamura Y, Akahira J, Ishida T: Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol. 2012, 227: 357-366. 10.1002/path.4019PubMed
33.
Yang Y, Wu J, Guan H, Cai J, Fang L, Li J, Li M: MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2. FEBS Lett. 2012, 586: 3608-3612. 10.1016/j.febslet.2012.08.003PubMed
34.
Lin T, Dong W, Huang J, Pan Q, Fan X, Zhang C, Huang L: MicroRNA-143 as a tumor suppressor for bladder cancer. J Urol. 2009, 181: 1372-1380. 10.1016/j.juro.2008.10.149PubMed
35.
Li Y, Vandenboom TG, Wang Z, Kong D, Ali S, Philip PA, Sarkar FH: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 2010, 70: 1486-1495. 10.1158/0008-5472.CAN-09-2792PubMedCentralPubMed
36.
Venkataraman S, Birks DK, Balakrishnan I, Alimova I, Harris PS, Patel PR, Handler MH, Dubuc A, Taylor MD, Foreman NK, Vibhakar R: MicroRNA 218 acts as a tumor suppressor by targeting multiple cancer phenotype-associated genes in medulloblastoma. J Biol Chem. 2013, 288: 1918-1928. 10.1074/jbc.M112.396762PubMedCentralPubMed
37.
Li B, Song Y, Liu TJ, Cui YB, Jiang Y, Xie ZS, Xie SL: miRNA-22 suppresses colon cancer cell migration and invasion by inhibiting the expression of T-cell lymphoma invasion and metastasis 1 and matrix metalloproteinases 2 and 9. Oncol Rep. 2013, 29: 1932-1938.PubMed
38.
Fuse M, Kojima S, Enokida H, Chiyomaru T, Yoshino H, Nohata N, Kinoshita T, Sakamoto S, Naya Y, Nakagawa M: Tumor suppressive microRNAs (miR-222 and miR-31) regulate molecular pathways based on microRNA expression signature in prostate cancer. J Human Genet. 2012, 57: 691-699. 10.1038/jhg.2012.95.
39.
Wang F, Wang XS, Yang GH, Zhai PF, Xiao Z, Xia LY, Chen LR, Wang Y, Wang XZ, Bi LX: miR-29a and miR-142-3p downregulation and diagnostic implication in human acute myeloid leukemia. Mol Biol Rep. 2012, 39: 2713-2722. 10.1007/s11033-011-1026-5PubMed
40.
Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Tanaka Y, Chiyomaru T: miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res: Off J Am Assoc Cancer Res. 2013, 19: 73-84. 10.1158/1078-0432.CCR-12-2952.
41.
Ueno K, Hirata H, Majid S, Yamamura S, Shahryari V, Tabatabai ZL, Hinoda Y, Dahiya R: Tumor suppressor microRNA-493 decreases cell motility and migration ability in human bladder cancer cells by downregulating RhoC and FZD4. Mol Cancer Ther. 2012, 11: 244-253. 10.1158/1535-7163.MCT-11-0592PubMedCentralPubMed
42.
Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol. 2007, 25: 387-392. 10.1016/j.urolonc.2007.01.019PubMed
43.
Vaksman O, Stavnes HT, Kaern J, Trope CG, Davidson B, Reich R: miRNA profiling along tumour progression in ovarian carcinoma. J Cell Mol Med. 2011, 15: 1593-1602. 10.1111/j.1582-4934.2010.01148.xPubMedCentralPubMed
44.
Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, Demidenko E, Korc M, Shi W, Preis M: MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest. 2010, 120: 1298-1309. 10.1172/JCI39566PubMedCentralPubMed
45.
McIver SC, Stanger SJ, Santarelli DM, Roman SD, Nixon B, McLaughlin EA: A unique combination of male germ cell miRNAs coordinates gonocyte differentiation. PLoS ONE. 2012, 7: e35553- 10.1371/journal.pone.0035553PubMedCentralPubMed
46.
Fan X, Chen X, Deng W, Zhong G, Cai Q, Lin T: Up-regulated microRNA-143 in cancer stem cells differentiation promotes prostate cancer cells metastasis by modulating FNDC3B expression. BMC Cancer. 2013, 13: 61- 10.1186/1471-2407-13-61PubMedCentralPubMed
47.
Peng X, Guo W, Liu T, Wang X, Tu X, Xiong D, Chen S, Lai Y, Du H, Chen G: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS ONE. 2011, 6: e20341- 10.1371/journal.pone.0020341PubMedCentralPubMed
48.
Xiao B, Zhu ED, Li N, Lu DS, Li W, Li BS, Zhao YL, Mao XH, Guo G, Yu PW, Zou QM: Increased miR-146a in gastric cancer directly targets SMAD4 and is involved in modulating cell proliferation and apoptosis. Oncol Rep. 2012, 27: 559-566.PubMed
49.
Vang S, Wu HT, Fischer A, Miller DH, Maclaughlan S, Douglass E, Steinhoff M, Collins C, Smith PJ, Brard L, Brodsky AS: Identification of Ovarian Cancer Metastatic miRNAs. PLoS ONE. 2013, 8: e58226- 10.1371/journal.pone.0058226PubMedCentralPubMed
50.
Leite KR, Sousa-Canavez JM, Reis ST, Tomiyama AH, Camara-Lopes LH, Sanudo A, Antunes AA, Srougi M: Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis. Urol Oncol. 2011, 29: 265-269. 10.1016/j.urolonc.2009.02.002PubMed
51.
Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang W, Jafferji M, Gordon JA, Li Z, Croce CM, van Wijnen AJ, Stein JL: miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012, 287: 42084-42092. 10.1074/jbc.M112.377515PubMedCentralPubMed
52.
Jiang R, Deng L, Zhao L, Li X, Zhang F, Xia Y, Gao Y, Wang X, Sun B: miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res: Off J Am Assoc Cancer Res. 2011, 17: 5593-5603. 10.1158/1078-0432.CCR-10-1734.
53.
Wang Z, Zhang H, He L, Dong W, Li J, Shan Z, Teng W: Association between the expression of four upregulated miRNAs and extrathyroidal invasion in papillary thyroid carcinoma. OncoTargets Ther. 2013, 6: 281-287.
54.
Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007, 14: 791-798. 10.1677/ERC-07-0129PubMed
55.
Han YC, Park CY, Bhagat G, Zhang J, Wang Y, Fan JB, Liu M, Zou Y, Weissman IL, Gu H: microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med. 2010, 207: 475-489. 10.1084/jem.20090831PubMedCentralPubMed
56.
Wu Q, Lu Z, Li H, Lu J, Guo L, Ge Q: Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotech. 2011, 2011: 597145-
57.
Watson JA, Bryan K, Williams R, Popov S, Vujanic G, Coulomb A, Boccon-Gibod L, Graf N, Pritchard-Jones K, O'Sullivan M: miRNA profiles as a predictor of chemoresponsiveness in Wilms' tumor blastema. PLoS ONE. 2013, 8: e53417- 10.1371/journal.pone.0053417PubMedCentralPubMed
58.
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni L, Zhang WG, Nan KJ, Song TS, Huang C: MicroRNA profiling of human gastric cancer. Mol Med Rep. 2009, 2: 963-970.PubMed
59.
Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH: Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing. PLoS ONE. 2012, 7: e34150- 10.1371/journal.pone.0034150PubMedCentralPubMed
60.
Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T: Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci. 2007, 98: 1845-1852. 10.1111/j.1349-7006.2007.00619.xPubMed
61.
Svoboda M, Sana J, Redova M, Navratil J, Palacova M, Fabian P, Slaby O, Vyzula R: MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol. 2012, 7: 31.62-
62.
Lehmann U, Streichert T, Otto B, Albat C, Hasemeier B, Christgen H, Schipper E, Hille U, Kreipe HH, Langer F: Identification of differentially expressed microRNAs in human male breast cancer. BMC Cancer. 2010, 10: 109- 10.1186/1471-2407-10-109PubMedCentralPubMed
63.
Yang H, Cho ME, Li TW, Peng H, Ko KS, Mato JM, Lu SC: MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest. 2013, 123: 285-298. 10.1172/JCI63861PubMedCentralPubMed
64.
Yang G, Zhang R, Chen X, Mu Y, Ai J, Shi C, Liu Y, Sun L, Rainov NG, Li H: MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status. J Mol Med. 2011, 89: 1037-1050. 10.1007/s00109-011-0775-xPubMed
65.
Hummel R, Hussey DJ, Michael MZ, Haier J, Bruewer M, Senninger N, Watson DI: MiRNAs and their association with locoregional staging and survival following surgery for esophageal carcinoma. Ann Surg Oncol. 2011, 18: 253-260. 10.1245/s10434-010-1213-yPubMed
66.
Zheng X, Chopp M, Lu Y, Buller B, Jiang F: MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett. 2013, 329: 146-154. 10.1016/j.canlet.2012.10.026PubMedCentralPubMed
67.
Sun L, Yao Y, Liu B, Lin Z, Lin L, Yang M, Zhang W, Chen W, Pan C, Liu Q: MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene. 2012, 31: 432-445. 10.1038/onc.2011.263PubMed
68.
Lui WO, Pourmand N, Patterson BK, Fire A: Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007, 67: 6031-6043. 10.1158/0008-5472.CAN-06-0561PubMed
69.
Michael MZ SMOC, van Holst Pellekaan NG, Young GP, James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003, 1: 882-891.PubMed
70.
Wei Q, Li YX, Liu M, Li X, Tang H: MiR-17-5p targets TP53INP1 and regulates cell proliferation and apoptosis of cervical cancer cells. IUBMB Life. 2012, 64: 697-704. 10.1002/iub.1051PubMed
71.
Hossain A, Kuo MT, Saunders GF: Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006, 26: 8191-8201. 10.1128/MCB.00242-06PubMedCentralPubMed
72.
Suh MR, Lee Y, Kim JY, Kim SK, Moon SH, Lee JY, Cha KY, Chung HM, Yoon HS, Moon SY: Human embryonic stem cells express a unique set of microRNAs. Dev Biol. 2004, 270: 488-498. 10.1016/j.ydbio.2004.02.019PubMed
73.
Tao J, Wu D, Li P, Xu B, Lu Q, Zhang W: microRNA-18a, a member of the oncogenic miR-17-92 cluster, targets Dicer and suppresses cell proliferation in bladder cancer T24 cells. Mol Med Rep. 2012, 5: 167-172.PubMed
74.
O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005, 435: 839-843. 10.1038/nature03677PubMed
75.
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO, Landthaler M: A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007, 129: 1401-1414. 10.1016/j.cell.2007.04.040PubMedCentralPubMed
76.
Wu H, Zhu S, Mo YY: Suppression of cell growth and invasion by miR-205 in breast cancer. Cell Res. 2009, 19: 439-448. 10.1038/cr.2009.18PubMedCentralPubMed
77.
Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ: Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene. 2012, 32: 2892-2899.
78.
Chang CC, Yang YJ, Li YJ, Chen ST, Lin BR, Wu TS, Lin SK, Kuo MY, Tan CT: MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral oncology. 2013, 49: 923-931. 10.1016/j.oraloncology.2013.03.430PubMed
79.
Sewer A, Paul N, Landgraf P, Aravin A, Pfeffer S, Brownstein MJ, Tuschl T, van Nimwegen E, Zavolan M: Identification of clustered microRNAs using an ab initio prediction method. BMC Bioinformatics. 2005, 6: 267- 10.1186/1471-2105-6-267PubMedCentralPubMed
80.
Stark MS, Tyagi S, Nancarrow DJ, Boyle GM, Cook AL, Whiteman DC, Parsons PG, Schmidt C, Sturm RA, Hayward NK: Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS ONE. 2010, 5: e9685- 10.1371/journal.pone.0009685PubMedCentralPubMed
81.
Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova J, Radova L, Fabian P, Slaba K, Kiss I: Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med. 2012, 16: 2655-2666. 10.1111/j.1582-4934.2012.01579.xPubMedCentralPubMed
82.
Berezikov E, van Tetering G, Verheul M, van de Belt J, van Laake L, Vos J, Verloop R, van de Wetering M, Guryev V, Takada S: Many novel mammalian microRNA candidates identified by extensive cloning and RAKE analysis. Genome Res. 2006, 16: 1289-1298. 10.1101/gr.5159906PubMedCentralPubMed
83.
Zhang M, Zhou S, Zhang L, Zhang J, Cai H, Zhu J, Huang C, Wang J: miR-518b is down-regulated, and involved in cell proliferation and invasion by targeting Rap1b in esophageal squamous cell carcinoma. FEBS Lett. 2012, 586: 3508-3521. 10.1016/j.febslet.2012.08.007PubMed
84.
Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA, Sjoblom T, Barad O, Bentwich Z, Szafranska AE, Labourier E: The colorectal microRNAome. Proc Natl Acad Sci U S A. 2006, 103: 3687-3692. 10.1073/pnas.0511155103PubMedCentralPubMed
85.
Fang Y, Xue JL, Shen Q, Chen J, Tian L: MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology. 2012, 55: 1852-1862. 10.1002/hep.25576PubMed
86.
Guo LM, Pu Y, Han Z, Liu T, Li YX, Liu M, Li X, Tang H: MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009, 276: 5537-5546. 10.1111/j.1742-4658.2009.07237.xPubMed
87.
Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, Bhatia J, Stadler Z, Fine SW, Reuter V: Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010, 16: 2115-2121. 10.1158/1078-0432.CCR-09-2871PubMedCentralPubMed
88.
Martin P, Liu YN, Pierce R, Abou-Kheir W, Casey O, Seng V, Camacho D, Simpson RM, Kelly K: Prostate epithelial Pten/TP53 loss leads to transformation of multipotential progenitors and epithelial to mesenchymal transition. Am J Pathol. 2011, 179: 422-435. 10.1016/j.ajpath.2011.03.035PubMedCentralPubMed
89.
Matsuda M, Miyagawa K, Takahashi M, Fukuda T, Kataoka T, Asahara T, Inui H, Watatani M, Yasutomi M, Kamada N: Mutations in the RAD54 recombination gene in primary cancers. Oncogene. 1999, 18: 3427-3430. 10.1038/sj.onc.1202692PubMed
90.
Bi X, Hameed M, Mirani N, Pimenta EM, Anari J, Barnes BJ: Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res. 2011, 13: R111- 10.1186/bcr3053PubMedCentralPubMed
91.
Lin SC, Chien CW, Lee JC, Yeh YC, Hsu KF, Lai YY, Lin SC, Tsai SJ: Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells. J Clin Invest. 2011, 121: 1905-1916. 10.1172/JCI44362PubMedCentralPubMed
92.
Liu B, Xia X, Zhu F, Park E, Carbajal S, Kiguchi K, DiGiovanni J, Fischer SM, Hu Y: IKKalpha is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell. 2008, 14: 212-225. 10.1016/j.ccr.2008.07.017PubMed
93.
Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak M, Fu D, Reddy S, Bell GW, Jaenisch R: Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression. Proc Natl Acad Sci U S A. 2011, 108: 18061-18066. 10.1073/pnas.1114946108PubMedCentralPubMed
94.
Jang MS, Lee SJ, Kim CJ, Lee CW, Kim E: Phosphorylation by polo-like kinase 1 induces the tumor-suppressing activity of FADD. Oncogene. 2011, 30: 471-481. 10.1038/onc.2010.423PubMed
95.
Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J: PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer. 2012, 12: 543- 10.1186/1471-2407-12-543PubMedCentralPubMed
96.
Qi W, Weber CR, Wasland K, Roy H, Wali R, Joshi S, Savkovic SD: Tumor suppressor FOXO3 mediates signals from the EGF receptor to regulate proliferation of colonic cells. Am J Physiol Gastrointest Liver Physiol. 2011, 300: G264-G272. 10.1152/ajpgi.00416.2010PubMedCentralPubMed
97.
Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Kudo Y, Goto T, Yoshida H, Koike K: A miRNA machinery component DDX20 controls NF-kappaB via microRNA-140 function. Biochem Biophys Res Commun. 2012, 420: 564-569. 10.1016/j.bbrc.2012.03.034PubMed
98.
Zhang Y, Linn D, Liu Z, Melamed J, Tavora F, Young CY, Burger AM, Hamburger AW: EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther. 2008, 7: 3176-3186. 10.1158/1535-7163.MCT-08-0526PubMedCentralPubMed
99.
Hakariya T, Shida Y, Sakai H, Kanetake H, Igawa T: EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells. Biochem Biophys Res Commun. 2006, 342: 92-100. 10.1016/j.bbrc.2006.01.106PubMed
100.
Cao YEG, Wang E, Pal K, Dutta SK, Bar-Sagi D, Mukhopadhyay D: VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 2012, 72: 3912-3918. 10.1158/0008-5472.CAN-11-4058PubMedCentralPubMed
101.
Aggarwal H, Aggarwal A, Agrawal DK: Epidermal growth factor increases LRF/Pokemon expression in human prostate cancer cells. Exp Mol Pathol. 2011, 91: 496-501. 10.1016/j.yexmp.2011.05.006PubMedCentralPubMed
102.
Bhatt DK, Nagda G: Modulation of acid phosphatase and lactic dehydrogenase in hexachlorocyclohexane-induced hepatocarcinogenesis in mice. J Biochem Mol Toxicol. 2012, 26: 439-444. 10.1002/jbt.21441PubMed
103.
Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Alcover J, Campo E, Gascon P, Rovira A: Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer. 2005, 93: 1285-1294. 10.1038/sj.bjc.6602851PubMedCentralPubMed
104.
Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, D'Urso L, Pagliuca A, Biffoni M, Labbaye C: The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008, 14: 1271-1277. 10.1038/nm.1880PubMed
105.
Berger E, Vega N, Vidal H, Geloen A: Gene network analysis leads to functional validation of pathways linked to cancer cell growth and survival. Biotechnol J. 2012, 7: 1395-1404. 10.1002/biot.201200188PubMed
106.
Derdak Z, Mark NM, Beldi G, Robson SC, Wands JR, Baffy G: The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res. 2008, 68: 2813-2819. 10.1158/0008-5472.CAN-08-0053PubMedCentralPubMed
107.
Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB, Williams H, Karanam S, Datta MW, Jaye DL, Moreno CS: Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res. 2006, 66: 4011-4019. 10.1158/0008-5472.CAN-05-3055PubMed
108.
Jin F, Irshad S, Yu W, Belakavadi M, Chekmareva M, Ittmann MM, Abate-Shen C, Fondell JD: ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. Mol Cancer Res. 2013, 11: 736-747. 10.1158/1541-7786.MCR-12-0618PubMed
109.
Wei J, Yuan Y, Jin C, Chen H, Leng L, He F, Wang J: The ubiquitin ligase TRAF6 negatively regulates the JAK-STAT signaling pathway by binding to STAT3 and mediating its ubiquitination. PLoS One. 2012, 7: e49567- 10.1371/journal.pone.0049567PubMedCentralPubMed
110.
Tiacci E, Grossmann V, Martelli MP, Kohlmann A, Haferlach T, Falini B: The corepressors BCOR and BCORL1: two novel players in acute myeloid leukemia. Haematologica. 2012, 97: 3-5. 10.3324/haematol.2011.057901PubMedCentralPubMed
111.
Iourov IY, Vorsanova SG, Liehr T, Kolotii AD, Yurov YB: Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum Mol Genet. 2009, 18: 2656-2669. 10.1093/hmg/ddp207PubMed
112.
Park SJ, Jang HR, Kim M, Kim JH, Kwon OH, Park JL, Noh SM, Song KS, Kim SY, Kim YH, Kim YS: Epigenetic alteration of CCDC67 and its tumor suppressor function in gastric cancer. Carcinogenesis. 2012, 33: 1494-1501. 10.1093/carcin/bgs178PubMed
113.
Srougi MC, Burridge K: The nuclear guanine nucleotide exchange factors Ect2 and Net1 regulate RhoB-mediated cell death after DNA damage. PLoS One. 2011, 6: e17108- 10.1371/journal.pone.0017108PubMedCentralPubMed
114.
Maity B, Stewart A, O'Malley Y, Askeland RW, Sugg SL, Fisher RA: Regulator of G Protein Signaling 6 (RGS6) is a novel suppressor of breast tumor initiation and progression. Carcinogenesis. 2013, 34: 1747-1755. 10.1093/carcin/bgt128PubMedCentralPubMed
115.
Sharma P, Patel D, Chaudhary J: Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1B. Cancer Med. 2012, 1: 187-197. 10.1002/cam4.19PubMedCentralPubMed
116.
Ha S, Iqbal NJ, Mita P, Ruoff R, Gerald WL, Lepor H, Taneja SS, Lee P, Melamed J, Garabedian MJ, Logan SK: Phosphorylation of the androgen receptor by PIM1 in hormone refractory prostate cancer. Oncogene. 2013, 32: 3992-4000. 10.1038/onc.2012.412PubMedCentralPubMed
117.
Bisbal C, Silverman RH: Diverse functions of RNase L and implications in pathology. Biochimie. 2007, 89: 789-798. 10.1016/j.biochi.2007.02.006PubMedCentralPubMed
118.
Long JZ, Cisar JS, Milliken D, Niessen S, Wang C, Trauger SA, Siuzdak G, Cravatt BF: Metabolomics annotates ABHD3 as a physiologic regulator of medium-chain phospholipids. Nat Chem Biol. 2011, 7: 763-765. 10.1038/nchembio.659PubMedCentralPubMed
119.
Hayashi A, Hiatari R, Tsuji T, Ohashi K, Mizuno K: p63RhoGEF-mediated formation of a single polarized lamellipodium is required for chemotactic migration in breast carcinoma cells. FEBS Lett. 2013, 587: 698-705. 10.1016/j.febslet.2013.01.043PubMed
120.
Ting HJ, Messing J, Yasmin-Karim S, Lee YF: Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. J Biol Chem. 2013, 288: 1-9. 10.1074/jbc.M112.395947PubMedCentralPubMed
121.
Itoh G, Kanno S, Uchida KS, Chiba S, Sugino S, Watanabe K, Mizuno K, Yasui A, Hirota T, Tanaka K: CAMP (C13orf8, ZNF828) is a novel regulator of kinetochore-microtubule attachment. EMBO J. 2011, 30: 130-144. 10.1038/emboj.2010.276PubMedCentralPubMed
122.
Srivastava SK, Bhardwaj A, Singh S, Arora S, McClellan S, Grizzle WE, Reed E, Singh AP: Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis. 2012, 33: 1149-1157. 10.1093/carcin/bgs134PubMedCentralPubMed
123.
Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, Kung HJ, Gao AC, Zou JX, Chen HW: Histone methyltransferase NSD2/MMSET mediates constitutive NF-kappaB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol. 2012, 32: 3121-3131. 10.1128/MCB.00204-12PubMedCentralPubMed
124.
Errington WJ, Khan MQ, Bueler SA, Rubinstein JL, Chakrabartty A, Prive GG: Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase. Structure. 2012, 20: 1141-1153. 10.1016/j.str.2012.04.009PubMed
125.
Yoon S, De Micheli G: Prediction and Analysis of Human microRNA Regulatory Modules. Conf Proc IEEE Eng Med Biol Soc. 2005, 5: 4799-4802.PubMed
126.
Cai C, Portnoy DC, Wang H, Jiang X, Chen S, Balk SP: Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res. 2009, 69: 5202-5209. 10.1158/0008-5472.CAN-09-0026PubMed
127.
Gandellini P, Folini M, Longoni N, Pennati M, Binda M, Colecchia M, Salvioni R, Supino R, Moretti R, Limonta P: miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009, 69: 2287-2295. 10.1158/0008-5472.CAN-08-2894PubMed
128.
Al-Sarraf N, Reiff JN, Hinrichsen J, Mahmood S, Teh BT, McGovern E, De Meyts P, O'Byrne KJ, Gray SG: DOK4/IRS-5 expression is altered in clear cell renal cell carcinoma. Int J Cancer. 2007, 121: 992-998. 10.1002/ijc.22776PubMed
129.
Lin SL, Chiang A, Chang D, Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA. 2008, 14: 417-424. 10.1261/rna.874808PubMedCentralPubMed
130.
Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A. 2006, 103: 12481-12486. 10.1073/pnas.0605298103PubMedCentralPubMed
131.
Pacifico F, Crescenzi E, Mellone S, Iannetti A, Porrino N, Liguoro D, Moscato F, Grieco M, Formisano S, Leonardi A: Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a. J Clin Endocrinol Metab. 2010, 95: 1421-1430. 10.1210/jc.2009-1128PubMed
132.
Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J: miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011, 208: 1189-1201. 10.1084/jem.20101823PubMedCentralPubMed
133.
Bazzoni F, Rossato M, Fabbri M, Gaudiosi D, Mirolo M, Mori L, Tamassia N, Mantovani A, Cassatella MA, Locati M: Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A. 2009, 106: 5282-5287. 10.1073/pnas.0810909106PubMedCentralPubMed
134.
Shahab SW, Matyunina LV, Hill CG, Wang L, Mezencev R, Walker LD, McDonald JF: The effects of MicroRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. BMC Med Genomics. 2012, 5: 33- 10.1186/1755-8794-5-33PubMedCentralPubMed
135.
Li M, Collins R, Jiao Y, Ouillette P, Bixby D, Erba H, Vogelstein B, Kinzler KW, Papadopoulos N, Malek SN: Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood. 2011, 118: 5914-5917. 10.1182/blood-2011-05-356204PubMedCentralPubMed
136.
Al-Ahmadi W, Al-Haj L, Al-Mohanna FA, Silverman RH, Khabar KS: RNase L downmodulation of the RNA-binding protein, HuR, and cellular growth. Oncogene. 2009, 28: 1782-1791. 10.1038/onc.2009.16PubMedCentralPubMed
137.
Ravid T, Heidinger JM, Gee P, Khan EM, Goldkorn T: c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes. J Biol Chem. 2004, 279: 37153-37162. 10.1074/jbc.M403210200PubMed
138.
Truitt L, Freywald T, DeCoteau J, Sharfe N, Freywald A: The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res. 2010, 70: 1141-1153. 10.1158/0008-5472.CAN-09-1710PubMed
139.
Baek KH, Hong ME, Jung YY, Lee CH, Lee TJ, Park ES, Kim MK, Yoo JH, Lee SW: Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization. Cancer Res Treat. 2012, 44: 50-56. 10.4143/crt.2012.44.1.50PubMedCentralPubMed
140.
Zhao X, Dou W, He L, Liang S, Tie J, Liu C, Li T, Lu Y, Mo P, Shi Y: MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene. 2013, 32: 1363-1372. 10.1038/onc.2012.156PubMed
141.
Kong X, Li G, Yuan Y, He Y, Wu X, Zhang W, Wu Z, Chen T, Wu W, Lobie PE, Zhu T: MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS ONE. 2012, 7: e41523- 10.1371/journal.pone.0041523PubMedCentralPubMed
142.
Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G: Identification of the miR-106b 25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal. 2010, 3: ra29-PubMedCentralPubMed
143.
Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, Chang I, Yamamura S, Tanaka Y, Chiyomaru T: miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2013, 19: 73-84. 10.1158/1078-0432.CCR-12-2952PubMedCentralPubMed
144.
Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, Verhaegh G, Schalken J, von Bergen M, Horn F, Hackermuller J: MiR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013, 32: 277-285. 10.1038/onc.2012.55PubMed
145.
Gong AY, Eischeid AN, Xiao J, Zhao J, Chen D, Wang ZY, Young CY, Chen XM: miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer. 2012, 12: 492- 10.1186/1471-2407-12-492PubMedCentralPubMed
146.
Kokontis J, Takakura K, Hay N, Liao S: Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res. 1994, 54: 1566-1573.PubMed
Metadata
Title
MicroRNA expressions associated with progression of prostate cancer cells to antiandrogen therapy resistance
Authors
Richard Ottman
Camha Nguyen
Robert Lorch
Ratna Chakrabarti
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-1

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Aldolase positively regulates of the canonical Wnt signaling pathway

Research

Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival

Research

Identification of a gene signature of a pre-transformation process by senescence evasion in normal human epidermal keratinocytes

Research

TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness

Review

Dynamics of double strand breaks and chromosomal translocations

Research

A 3′UTR polymorphism modulates mRNA stability of the oncogene and drug target Polo-like Kinase 1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits